Vanguard Group Inc Fate Therapeutics Inc Call Options Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding FATE
# of Institutions
150Shares Held
83.4MCall Options Held
179KPut Options Held
13.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$12.4 Million1.75% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$9.71 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.54MShares$4.36 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.4MShares$3.26 Million0.0% of portfolio
-
Johnson & Johnson New Brunswick, NJ3.38MShares$3.24 Million1.27% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $93.1M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...